MilliporeSigma in the news

MilliporeSigma executive Sebastian Arana detailed the operational and financial challenges manufacturing facilities face when transitioning to multi-modality production, including cost management and scaling issues for advanced therapies.

Sebastian Arana discusses manufacturing flexibility challenges in multi-modality production, cell and gene therapy, mRNA, and ADC manufacturing.

MilliporeSigma's new Millipore Express® Ace 0.2 µm filters offer improved sustainable sterile filtration with a lower environmental impact and enhanced performance.

MilliporeSigma's Millipore Express® Ace filters offer enhanced sustainability and performance through innovative design and manufacturing processes.

Millipore Express Ace filters offer improved sustainable sterile filtration with reduced environmental impact and enhanced performance.

MilliporeSigma introduces Millipore Express® Ace 0.2 µm filters, a sustainable bioprocessing solution with enhanced performance and reduced environmental impact.

MilliporeSigma's SPARK™ program marks 10 years of employee volunteering, delivering hands-on science education and community support to over 600,000 students worldwide.

MilliporeSigma inaugurated a new •25 million BioReliance testing facility in Darmstadt, Germany, to expand drug substance and product release testing for European biopharmaceutical companies.

MilliporeSigma opened a new $29 million biologics testing facility in Darmstadt, Germany, enhancing its European capabilities for commercial drug release testing.

MilliporeSigma opened a new •25 million BioReliance testing facility in Darmstadt, Germany, to expand drug substance and product testing for European biopharmaceutical companies.

MilliporeSigma opened a new •25 million BioReliance testing facility in Darmstadt, Germany, to expand drug product release and stability testing services in Europe.

MilliporeSigma opened a new •25 million BioReliance testing facility in Darmstadt, Germany, to expand drug product release and stability testing services for European biopharmaceutical companies.

MilliporeSigma inaugurated a  25 million BioReliance facility in Germany to enhance drug release and stability testing for European biopharmaceutical companies.

MilliporeSigma awarded its 2026 North American Advance Biotech Grant to Hiba Therapeutics for its TROIKA platform targeting solid tumors.

Hiba Therapeutics won the 2026 North American Advance Biotech Grant to accelerate the development of its targeted oncology biologics platform.

MilliporeSigma executive Sebastián Arana identifies modular platforms and workforce modernization as critical factors for scaling complex biopharmaceutical manufacturing.

MilliporeSigma launched a line of bio-based HPLC and LCMS solvents at CHEMUK 2026 to reduce laboratory carbon footprints without altering scientific workflows.

MilliporeSigma is integrating its vast life science portfolio with AI and automation to create closed-loop labs that design, synthesize, and test molecules with minimal human intervention.

MilliporeSigma has appointed new heads for its Discovery Solutions and Strategy & Business Development units to drive growth and digital transformation.

MilliporeSigma has appointed new heads for its Discovery Solutions and Strategy & Business Development units to drive innovation and inorganic growth.